Selected Original Articles

1. Clark CC, Crossland J, Kaplan G, Martinez-Hernandez, A. Location and identification of the collagen found in the 14.5-d rat embryo visceral yolk sac. J Cell Biology 93:251-260, 1982
2. Arana GW, Kaplan GB. Trazodone-induced mania following desipramine-induced mania in major depressive disorders. Am J Psychiatry 142:386, 1985
3. Kaplan GB, Greenblatt DJ, LeDuc BW, Thompson ML, Shader RI. Relationship of plasma and brain caffeine metabolites to benzodiazepine receptor binding and locomotor activity. J Pharmacol Exp Ther 248:1078-1083, 1989
4. Lopez F, Miller LG, Greenblatt DJ, Kaplan GB, Shader RI. Interaction of caffeine with the GABAA receptor complex: alterations in receptor function but not ligand binding. Eur J Pharmacol 172:453-459, 1989
5. Kaplan GB, Tai NT, Greenblatt DJ, Shader RI. Separate and combined effects of caffeine and alprazolam on motor activity and benzodiazepine receptor binding in vivo. Psychopharmacology 101:539-544, 1990
6. Kaplan GB, Tai NT, Greenblatt DJ, Shader RI. Caffeine-induced behavioral stimulation is dose- and concentration-dependent. Brit J Pharmacol 100:435-440, 1990
7. Kaplan GB, Greenblatt DJ, Kent MA, Cotreau MM, Arcelin G, Shader RI. Caffeine-induced behavioral stimulation is dose-dependent and associated with A1 adenosine receptor occupancy. Neuropsychopharmacology 6:145-153, 1992
8. Kaplan GB, Cotreau MM, Greenblatt DJ. Effects of benzodiazepine administration on A1 adenosine receptor binding in vivo and ex vivo. J Pharm Pharmacol 44:700-703, 1992
9. Kaplan GB, Kent MA, Cotreau-Bibbo MM, Greenblatt DJ. Caffeine treatment and withdrawal in mice: Relationships between dosage, concentrations, locomotors activity and A1 adenosine receptor binding. J Pharmacol Exp Ther 266:1563-1572, 1993
10. Kaplan GB, Leite-Morris KA, Sears MT. Alterations in adenosine A1 receptors in morphine dependence. Brain Res 657: 347-350, 1994
11. Kaplan GB, Sears MT. Adenosine receptor agonists attenuate and antagonist’s excerbate opiate withdrawal signs. Psychopharmacology 123:64-70, 1996
12. Kaplan GB, Greenblatt DJ, Ehrenberg BL, Goddard JE, Cotreau MM, Harmatz JS, Shader RS. Dose-dependent pharmacokinetics and psychomotor effects of caffeine in humans. J Clin Pharmacol 37:693-703, 1997
13. Kaplan GB, Leite-Morris KA. Up-regulation of adenosine transporter binding sites in striatum and hypothalamus of morphine tolerant mice. Brain Res 763:215-220, 1997
14. Kaplan GB, Greenblatt DJ, Ehrenberg BL, Goddard JE, Harmatz JS, Shader RS. Single-dose alprazolam pharmacokinetics and pharmacodynamics in the elderly. J Clin Pharmacol 38:14-21, 1998
15. Kaplan GB, Leite-Morris KA, Sethi RK, McClelland EG. Regulation of G protein-mediated adenylyl cyclase activity in striatum and cortex of opiate-dependent and opiate-withdrawing mice. Brain Res 788:104-110, 1998
16. Leite-Morris KA, Kaplan GB, Smith JG, Sears MT. Alterations in G proteins and adenylyl cyclase in brain regions of caffeine-tolerant and -dependent mice. Brain Res 804:52-62, 1998
17. Kaplan GB, Coyle TS. Adenosine kinase inhibitors attenuate opiate withdrawal via adenosine receptor activation. Eur J Pharmacol 362:1-8, 1998
18. Weisberg SP, Kaplan GB. Adenosine receptor antagonists inhibit the development of morphine-induced sensitization in the C57BL/6 mouse. Neurosci Lett 264:1-4, 1999
19. Kaplan GB, Bharmal NP, Leite-Morris KA, Adams, WR. Role of adenosine A1 and A2a receptors in the alcohol withdrawal syndrome. Alcohol 19:157-162, 1999
20. Kaplan GB, Leite-Morris KA, Keith DJ. Differential effects of chronic treatment with typical and atypical antipsychotic drugs on G proteins and adenylyl cyclase. Neurosci Lett 273:147-150, 1999
21. Kaplan GB, Greenblatt DJ, Ehrenberg BL, Goddard JE, Harmatz JS, Shader RS. Differences in pharmacodynamics but not pharmacokinetics between subjects with panic disorder and healthy subjects after treatment with a single-dose of alprazolam. J Clin Psychopharmacol 20: 338-346, 2000
22. Rohsenow DJ, Monti PM, Hutchinson KE, Swift RM, Colby SM, Kaplan GB. Naltrexone’s effects on reactivity to alcohol cues among alcoholic men. J Abnormal Psychology 109:738-742, 2000
23. Pande AC, Crockatt JG, Janney CA, Tsarouch G, Werth JL, Gabapentin Bipolar Study Group (Site Investigator). Gabapentin in Bipolar Disorder: a placebo-controlled trial of adjunctive medication. Bipolar Disorders 2:249-255, 2000
24. Krystal JH, Cramer JA, Krol WF, Kirk MA, Rosenheck RA, for the Veterans Affairs Naltrexone Cooperative Study 425 Group (Site Investigator). Naltrexone in the treatment of alcohol dependence. New Engl J Med 345: 1734-1739, 2001
25. Leite-Morris KA, Fukudome EY, Kaplan GB. Opiate-induced motor stimulation is regulated by gamma-aminobutyric acid type B receptors found in the ventral tegmental area. Neurosci Lett 317: 119-122, 2002
26. Kaplan GB, Leite-Morris KA, Joshi M, Shoeb M, Carey R. Baclofen inhibits opiate-induced conditioned place preference and associated induction of Fos in cortical and limbic regions. Brain Res 987: 122-125, 2003
27. Leite-Morris KA, Fukudome EY, Shoeb M, Kaplan GB. GABAB receptor activation in the ventral tegmental area blocks opiate-induced motor stimulation and sensitization. J Pharmacol Exp Ther 308:667-678, 2004
28. Turalba AV, Leite-Morris KA, Kaplan GB. Antipsychotic drug treatment regulates cAMP-dependent protein kinase and phosphorylation of cyclic AMP response-element binding protein in cortical and striatal regions. Neurosci Lett 357:53-57, 2004
29. Kaplan GB, McRoberts L, Smokler, H. Baclofen as adjunctive treatment for a patient with cocaine dependence and schizoaffective disorder. J Clin Psychopharmacol 24:574, 2004
30. Kranzler HR, Wesson DR, Billot L and the Drug Abuse Sciences Naltrexone Depot Study Group (Site Investigator). Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled study. Alcoholism: Clin Exp Res 28:1051-1059, 2004
31. Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM. Subjective and physiological responses to smoking cues in smokers with schizophrenia, Nicotine Tobacco Res 7:421–429, 2005
32. Tidey JW, Rohsenow DJ, Kaplan GB, Swift RM. Cigarette smoking topography in smokers with schizophrenia and matched non-psychiatric controls, Drug Alcohol Depend 80:259-65, 2005
33. Epstein-Lubow G, Hochstadt J, Lieberman P, Kaplan GB. Speech production in schizophrenia: a pilot investigation of voice onset time. Schizophrenia Res 82:267-9, 2006
34. Kaplan GB, Phillips KA, Vaccaro A, Eisen JL, Posternak MA, MacAskill HS. Assessment of insight into delusionality in schizophrenia and schizoaffective disorder using the Brown Assessment of Beliefs Scale. Schizophrenia Res 82:279-281, 2006
35. Rohsenow DJ, Monti PM, Hutchison KE, Swift RM, MacKinnon SV, Sirota AD, Kaplan GB. High dose transdermal nicotine and naltrexone: effects on nicotine withdrawal, urges, smoking, and effects of smoking. Experimental and Clinical Psychopharmacology 15:81-92, 2007

Books, Reviews and Chapters

1. Kaplan, GB. Neurobiological aspects of panic disorder. R I Med. 1992 May;75(5):247-51
2. Kaplan, GB and Bauer, MS. Anxiety disorders: Diagnoses, courses and treatments. In: Encyclopedia of Disability and Rehabilitation. ed. by AE Dell Orto and RP Marinelli, pp. 65-68, Macmillan Publishing Co, New York, 1995
3. Kaplan, GB and Hammer, RP (Editors). Brain Circuitry and Signaling in Psychiatry: Basic Science and Clinical Implications, American Psychiatric Press Inc (ISBN# 0-88048-957-X), Washington, DC, 2002
4. Kaplan, GB and Leite-Morris, KA. Introduction to neuronal signaling pathways. In: Brain Circuitry and Signaling in Psychiatry: Basic Science and Clinical Implications, ed. by GB Kaplan and RP Hammer, American Psychiatric Press Inc., Washington, DC, 2002